Recent work shows that the transcriptional coactivator Yorkie, which is negatively regulated by the Hippo tumor suppressor pathway, promotes the transcription of the proto-oncogene Myc and requires Myc function to drive growth. In turn, Myc keeps the concentration of Yorkie in check via negative feedback regulation.
Hugo Stocker
Genetic analyses in the model organism Drosophila melanogaster have revealed key players in growth control, such as the insulin/insulin-like growth factor signaling (IIS)/target of rapamycin (TOR) pathway, the Hippo tumor suppressor pathway, and the proto-oncoprotein dMyc. Whereas IIS/TOR signaling controls cellular growth and cell size in accordance with the nutritional status [1] , Hippo signaling restricts proliferation by controlling cell-cycle progression, apoptosis, and cellular growth [2] . Hippo pathway activity culminates in the phosphorylation and nuclear exclusion of the transcriptional coactivator Yorkie (Yki), thereby hindering it from inducing the expression of target genes that inhibit apoptosis (e.g., Diap1), stimulate cell-cycle progression (e.g., CycE), and promote cellular growth (e.g., the microRNA bantam) [2] . The proto-oncoprotein and transcription factor dMyc induces cellular growth by increasing the expression of numerous target genes, many of which promote ribosome biogenesis [3, 4] . However, the signals dictating where, when and at which levels dMyc is expressed have remained largely enigmatic. Two recent studies now reveal that dMyc is a target gene of Yki [5, 6] . Furthermore, negative feedback regulation from dMyc to Yki is proposed to balance growth [5] .
dMyc has emerged as a key player in cell competition where weak cells ('losers') get eliminated by apoptosis when surrounded by fitter cells ('winners'). It has been demonstrated that the survival decision depends on differences in dMyc levels between cell populations: cells with high dMyc expression will outcompete neighbors with less dMyc protein [7, 8] . Loss-of-function mutations in genes encoding Hippo pathway members have been shown to counteract cell competition [9] (although this study used a different experimental system to induce cell competition). Apparently, the increased Yki activity in these mutants is sufficient to overcome the death signals imposed by fitter surrounding cells. However, it has been unclear whether the induction of the caspase inhibitor Diap1 by Yki would simply block the induction of apoptosis and thereby keep loser cells alive, or whether there is a more intimate relationship between cell competition and Hippo signaling. To clarify this issue, the groups of Daniela Grifoni and Laura Johnston have now investigated connections between dMyc and the Hippo pathway [5, 6] .
Both teams used sophisticated genetic tools to generate mosaic animals consisting of patches of genotypically different cells, thus enabling them to investigate the consequences of the juxtaposition of cells with manipulated dMyc and/or Hippo signaling activities in the context of a growing epithelium. Most of the analyses were carried out in wing imaginal discs -single-cell layered epithelia that will eventually differentiate into the wings of the adult fly. The discs were typically dissected from third instar larvae to visualize the growth behavior of the genetically manipulated cell populations.
Clones of cells with high Yki activity (e.g., by overexpression of Yki) displayed characteristics of winner cells: not only did they grow larger, but they also impacted on the growth capacity of the neighboring wild-type cells (by non-autonomously inducing apoptosis). Conversely, cells lacking Yki grew very poorly, and their neighbors performed better than control cells. Since these effects were reminiscent of the consequences of elevated and reduced dMyc levels, respectively, the authors analyzed dMyc levels in the clones. They noticed an increase in dMyc protein levels that coincided with high Yki activity and, conversely, a reduction in the amounts of dMyc in situations where Yki activity was lowered, suggesting that dMyc expression is under the control of Yki. Expression analyses by mRNA in situ hybridization and by using reporter genes (transposon insertions in the diminutive (dm; [5] revealed that some of these sites were indeed bound by Sd and Yki.
Is the induction of dMyc expression required for Yki's growth-promoting effect? Yki-overexpressing cells that were concomitantly mutant for dMyc failed to overgrow and to outcompete their neighbors, suggesting that dMyc is necessary for the Yki-mediated supercompetitive behavior. However, dMyc expression is not sufficient: the growth of clones of yki mutant cells could not be restored by the expression of dMyc, either alone or in combination with the caspase inhibitors Diap1 or p35. Thus, additional target genes of Ykicontaining transcriptional complexes are required to promote growth.
Ziosi and colleagues [6] tested how Yki-overexpressing cells (i.e. cells with increased amounts of dMyc) behaved when facing cells with even higher dMyc levels. In this scenario, the Yki-overexpressing cells failed to outcompete their neighbors, and the resulting clones were both smaller and less numerous. Therefore, these authors propose that depending on the context (e.g. the Myc levels within the affected tissue), cell competition either promotes or suppresses tumor growth.
The discovery of dMyc as a target gene of Yki significantly advances our understanding of the Hippo tumor suppressor pathway, but the story becomes even more exciting. Neto-Silva and colleagues [5] noticed that Yki protein levels were higher in cells with reduced dMyc function. Conversely, overexpression of dMyc resulted in lower Yki levels. Both transcriptional and post-transcriptional mechanisms appear to contribute to the regulation of Yki in response to altered dMyc levels (although the experiments do not rule out the involvement of a microRNA that destabilizes yki mRNA). Importantly, the increase in Yki protein upon low dMyc activity did not change Yki's subcellular localization -the excess Yki protein was predominantly cytoplasmic. Consistently, reducing dMyc levels was not sufficient to induce Yki target genes. Overexpression of dMyc, on the other hand, decreased the induction of Yki target genes. These findings are consistent with a regulatory feedback mechanism: Yki-dependent transcription results in dMyc expression; dMyc in turn downregulates the amount of Yki. Such negative feedback regulation could ensure that Yki-induced growth does not go awry.
Thus, Yki activity is kept in check in at least two different ways (Figure 1 ): its subcellular localization is regulated by (phosphorylation-dependent and phosphorylation-independent) cytoplasmic retention mediated by Hippo signaling [2,10,11], and its protein concentration is controlled by dMyc [5] . This model predicts that, in mutants preventing the phosphorylation of Yki, a reduction in dMyc levels should result in larger amounts of Yki protein that is no longer retained in the cytoplasm, which is exactly what Neto-Silva and colleagues [5] observed in their experiments. Furthermore, disabling the negative feedback should unearth the combined growth potentials of Yki and dMyc. Although the constant supply of Yki from a transgene does not abolish its post-transcriptional containment, it may override the negative regulation. In fact, co-overexpression of dMyc and Yki significantly enhanced growth. In addition, the negative feedback may also explain the reported dMyc-induced cell-autonomous apoptosis [8, 12] . As high levels of dMyc reduce cellular Yki concentration, less Yki will be available in the nucleus to induce Diap1 expression. The shortage in Diap1 in turn renders the cells susceptible to apoptosis. In keeping with this notion, apoptosis was reduced in dMyc-overexpressing cells concomitantly mutant for Hippo signaling (thus having more nuclear Yki). Thus, the negative feedback may also act as a safeguard mechanism to restrict the growth potential of cells with abnormally high Myc levels.
The proposed growth-regulatory circuit involving Yki and dMyc not only integrates the activities of two potent growth promoters but also provides a means to balance growth. dMyc, induced by nuclear Yki, ensures that Yki does not accumulate in the cell, thus restricting nuclear Yki in concert with the Hippo signaling pathway, which imposes control on Yki's subcellular localization. Since Yki is such a potent growth inducer (by inhibiting apoptosis, driving cell-cycle progression and promoting cellular growth), it is conceivable that its activity is confined by different mechanisms acting in parallel. The negative feedback by dMyc is, at least to some extent, bypassed by overexpression of Yki. Interestingly, overexpression of YAP, the mammalian homolog of Yki, also induced the expression of c-Myc and resulted in liver cancer resembling hepatocellular carcinoma in mice [13] , and YAP overexpression is common in a variety of solid tumors [2, 14] . However, it remains to be determined whether the regulatory relationship between YAP and Myc also exists in mammals. Furthermore, it will be of great importance to identify the mechanism by which Myc controls the expression of Yki.
